Histogenics to serve as shell for Pennsylvania biotech in reverse-merger

Beleaguered cell therapy firm Histogenics Corp., which has appeared headed toward bankruptcy or a shutdown in recent months, announced Monday that it will be absorbed by a private Pennsylvania biopharma. Histogenics (Nasdaq: HSGX) has signed a reverse-merger with rare eye disease company Ocugen Inc., through which the privately held company will go public, according to a press release. The new company will move forward with Ocugen's name and headquarters, and no Histogenics employees will have job s…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news